NASDAQ
MENLO PARK, Calif. , Dec. 15, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company managemen...
Caxton Associates LLP bought a new stake in GRAIL, Inc. (NASDAQ: GRAL) during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 64,56...
Early cancer detection is highly beneficial to sufferers, and Grail's Galleri test offers a solution. The company is the leader in the race for FDA approval, but it could benefit from being part of a ...
MENLO PARK, Calif. , Dec. 1, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that it has granted equ...
Weary of being captive to geopolitics, car companies are looking for ways to replace powerful rare-earth magnets in electric motors....
Deutsche Bank appears to have set a high mark when it comes to forecasts for the S&P 500 in 2026, with a target of 8,000....
Retail investors are understandably on edge after several sessions of market volatility. But bestselling author and Oxford Club strategist Alexander Green, in his new book The American Dream, says we'...
MENLO PARK, Calif. , Nov. 18, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company managemen...
The cancer diagnostics specialist received two price target increases from separate analysts. One more than doubled his on the company....
Grail (GRAL) reported Q3 revenues of $36.2m, up 26% YoY, but continues to post significant losses and faces commercial challenges. Galleri test's PATHFINDER 2 study showed promising early cancer detec...
No price data available for this timeframe.